

Human TFPI Protein

Cat. No. TFP-HM201



Description

Source	Recombinant Human TFPI Protein is expressed from HEK293 with hFc (IgG1) tag at the C-terminus.
	It contains Asp29-Lys282.
Accession	P10646-1
Molecular Weight	The protein has a predicted MW of 55.11 kDa. Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Oestrogens influence the pathophysiology and development of hormone-sensitive cancers, such as breast cancer. Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor of the extrinsic coagulation pathway and has recently been associated with breast cancer cell development.


Assay Data

Bis-Tris PAGE



Human TFPI on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human TFPI is greater than 95% as determined by SEC-HPLC.

Human TFPI Protein

Cat. No. TFP-HM201



Assay Data

Bioactivity Data

Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, the IC₅₀ value is < 0.75 nM.